86P Impact of renal impairment on chemotherapy-induced neutropenia in patients who are treated with trifluridine/thymidine phosphorylase inhibitor + bevacizumab for metastatic colorectal cancer.

MLA

Shibutani, M., et al. “86P Impact of Renal Impairment on Chemotherapy-Induced Neutropenia in Patients Who Are Treated with Trifluridine/Thymidine Phosphorylase Inhibitor + Bevacizumab for Metastatic Colorectal Cancer.” Annals of Oncology, vol. 35, Dec. 2024, p. S1437. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.10.108.

APA

Shibutani, M., Tanda, H., Kasashima, H., Fukuoka, T., Kashiwagi, S., & Maeda, K. (2024). 86P Impact of renal impairment on chemotherapy-induced neutropenia in patients who are treated with trifluridine/thymidine phosphorylase inhibitor + bevacizumab for metastatic colorectal cancer. Annals of Oncology, 35, S1437. https://doi.org/10.1016/j.annonc.2024.10.108

Chicago

Shibutani, M., H. Tanda, H. Kasashima, T. Fukuoka, S. Kashiwagi, and K. Maeda. 2024. “86P Impact of Renal Impairment on Chemotherapy-Induced Neutropenia in Patients Who Are Treated with Trifluridine/Thymidine Phosphorylase Inhibitor + Bevacizumab for Metastatic Colorectal Cancer.” Annals of Oncology 35 (December): S1437. doi:10.1016/j.annonc.2024.10.108.